AKEEGA Drug Patent Profile

When do Akeega patents expire, and what generic alternatives are available?

Akeega is a drug marketed by Janssen Biotech and is included in one NDA. There are thirteen patents protecting this drug.

The generic ingredient in AKEEGA is abiraterone acetate; niraparib tosylate. One supplier is listed for this compound. Additional details are available on the abiraterone acetate; niraparib tosylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Akeega

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 27, 2031. This may change due to patent challenges or generic licensing.

There have been thirteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AKEEGA

US Patents:	13
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AKEEGA

US Patents and Regulatory Information for AKEEGA

AKEEGA is protected by twenty-two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,071,623.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	AKEEGA	abiraterone acetate; niraparib tosylate	TABLET;ORAL	216793-002	Aug 11, 2023		RX	Yes	Yes	8,436,185		Y	Y
Janssen Biotech	AKEEGA	abiraterone acetate; niraparib tosylate	TABLET;ORAL	216793-002	Aug 11, 2023		RX	Yes	Yes	12,383,543
Janssen Biotech	AKEEGA	abiraterone acetate; niraparib tosylate	TABLET;ORAL	216793-002	Aug 11, 2023		RX	Yes	Yes	11,986,470
Janssen Biotech	AKEEGA	abiraterone acetate; niraparib tosylate	TABLET;ORAL	216793-001	Aug 11, 2023		RX	Yes	No	11,986,468

International Patents for AKEEGA

When does loss-of-exclusivity occur for AKEEGA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Austria

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AKEEGA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2018246214	Niraparib compositions
Australia	2021245223	Niraparib compositions
Brazil	112019020211	composições de niraparib
Canada	3058375	COMPOSITIONS DE NIRAPARIB (NIRAPARIB COMPOSITIONS)

Supplementary Protection Certificates for AKEEGA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2240466	C201830027	Spain		PRODUCT NAME: NIRAPARIB; NATIONAL AUTHORISATION NUMBER: EU/1/17/1235; DATE OF AUTHORISATION: 20171116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1235; DATE OF FIRST AUTHORISATION IN EEA: 20171116
2109608	18C1019	France		PRODUCT NAME: NIRAPARIB OU L'UN DE SES SELS,STEREOISOMERES OU TAUTOMERES PHARMACEUTIQUEMENT ACCEPTABLES EN PARTICULIER LE TOSYLATE OU HYDRATE DE TOSYLATE,PLUS PARTICULIEREMENT LE TOSYLATE DE NIRAPARIB MONOHYDRATE; REGISTRATION NO/DATE: EU/1/17/1235 20171120
3490560	PA2025528	Lithuania		PRODUCT NAME: NIRAPARIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC NIRAPARIBO TOZILATAS, YPAC NIRAPARIBO TOZILATO MONOHIDRATAS, PASIRINKTINAI DERINYJE SU ABIRATERONU, YPAC ABIRATERONO ACETATU; REGISTRATION NO/DATE: EU/1/23/1722 20230419
1633724	S1500012	Hungary		PRODUCT NAME: OLAPARIB

Last updated: April 23, 2026

AKEEGA (Akeega): Investment scenario and fundamentals analysis

What is AKEEGA and what risks drive the investment case?

AKEEGA is the fixed-dose combination of niraparib (PARP inhibitor) plus abiraterone acetate (and prednisone) for metastatic castration-resistant prostate cancer (mCRPC). The investment case hinges on whether payers and clinicians treat AKEEGA as a durable, differentiated standard-of-care option versus branded and generic abiraterone, and whether uptake accelerates beyond the initial label anchor populations.

Key investment drivers and constraints:

• Clinical differentiation depends on label position: AKEEGA’s value is concentrated in the specific indication(s) and line-of-therapy placements where niraparib meaningfully improves outcomes relative to abiraterone-based regimens.
• Competitive pressure is structural: androgen receptor pathway inhibitors (ARPI) and other PARP inhibitors compete on sequencing rules, biomarker coverage, and tolerability.
• Safety and adherence affects net realization: PARP inhibitor class signals drive dose modifications, discontinuations, and pharmacy utilization under real-world constraints.
• Patent and exclusivity maturity determines long-term economics: combination products and component patents can create staggered erosion windows for market protection.

---

What does the market tell you about demand durability?

Demand durability for AKEEGA is a function of:

• How quickly clinicians adopt niraparib-augmented ARPI regimens for mCRPC.
• Biomarker-driven targeting (when applicable) that can cap addressable population.
• Payer requirements that often favor narrower criteria earlier, then broaden if evidence and budget impact support expansion.

Commercial durability signals to track:

• Quarterly prescription counts vs. patient starts (lagging indicator: treatment duration).
• Share of voice in urology/oncology networks where sequencing decisions concentrate.
• Real-world discontinuation rate and dose intensity relative to label expectations, which influences reorder behavior.

---

What are the fundamentals of the drug’s competitive positioning?

AKEEGA competes along two axes:

1. With ARPI regimens (abiraterone acetate, enzalutamide, etc.) used across mCRPC lines.
2. With other PARP inhibitor strategies (either as monotherapy or combined with hormonal agents, depending on label).

Net effect:

• If AKEEGA is priced at a premium, it must show outcomes that translate into payer willingness-to-pay.
• If AKEEGA’s adoption is limited to narrow subsets, the revenue curve can flatten even without immediate safety setbacks.

---

What is the payer and access reality for an oral combination?

AKEEGA is an oral fixed-dose regimen. Oral oncology adoption still runs into common access constraints:

• Formulary placement: specialty pharmacy channels and prior authorization (PA) requirements control uptake.
• Step therapy and sequencing rules: payers may require documentation of ARPI exposure or resistance status where clinically consistent.
• Reimbursement dynamics: cost-sharing design can affect persistence and adherence, particularly early during uptake.

Investment implication: a model that assumes linear penetration without PA friction will overstate early-year revenue and understate churn.

---

What are the key clinical and safety fundamentals affecting commercial performance?

For PARP inhibitor-based strategies, the commercial KPI set typically includes:

• Adverse event burden leading to dose interruption
• Hematologic toxicities driving monitoring and lab cadence
• Treatment discontinuation rates
• Patient persistence (time-on-therapy)

Investment implication: AKEEGA’s patient journey profile will determine whether sales are “starts-led” or “duration-led.” A starts-led product can still deliver revenues, but it is more exposed to rapid competitive sequencing changes.

---

How does patent and exclusivity timing shape long-range value?

Investment-grade valuation of AKEEGA requires a scenario of:

• Component protection overlap: niraparib and abiraterone have distinct protection landscapes.
• Combination product protection: fixed-dose formulation and method-of-use can extend exclusivity where allowed.
• Regulatory exclusivities and any supplemental protection windows: can delay generic entry even if single-agent protection weakens.

The investment model should treat the protection stack as staggered erosion, not a single cliff.

---

Investment scenario modeling: base, bull, bear

What revenue scenario range fits the adoption and competition structure?

A practical investment scenario framework:

Scenario	Adoption profile	Competition response	What you expect in KPIs
Bear	Limited label uptake; narrow payer coverage early	ARPI incumbents retain share	Lower patient starts, shorter persistence, higher discontinuation
Base	Moderate adoption with payer stabilization	Stronger than historical benchmarks for combo regimens	Starts rise then normalize; persistence improves with experience
Bull	Broadening criteria post-evidence; smoother PA pathways	Incumbents lose share faster	Higher treatment duration, stronger net retention, better dose intensity

Investment implication: the spread between bear and bull should come more from persistence and net pricing than from headline patient starts alone.

---

What cost and margin levers matter most?

For an oncology combination like AKEEGA, margin sensitivity typically concentrates in:

• Specialty pharmacy distribution costs and rebate structures tied to volume and access design.
• Drug substance and formulation cost efficiency (fixed-dose efficiency can be favorable).
• Realization pressure if payers shift to “lowest net cost” contracting under competitive class dynamics.

Investment implication: margin models should apply net price erosion curves tied to competition and coverage change rather than holding gross-to-net constant.

---

What are the key diligence checkpoints for an investor?

Critical diligence points for AKEEGA:

• Utilization data: patient starts, persistence, and discontinuation by line-of-therapy.
• Net pricing: payer-specific WAC-to-net conversion, rebate volatility, and contract renegotiations.
• Safety and tolerability in real-world cohorts: dose modifications and lab monitoring burden.
• Competitive churn: evidence of share movement relative to ARPI and other PARP pathways.
• Pipeline and label expansion exposure: whether AKEEGA’s moat grows via new populations or shrinks due to better alternatives.

---

Key takeaways

• AKEEGA’s investment thesis is adoption-plus-persistence: revenue quality depends on patient duration and net realization after payer friction.
• Competitive pressure is layered: it faces ARPI incumbents and PARP strategies with different sequencing rules and biomarker coverage.
• Valuation is protection-stack driven: long-term value depends on staggered component and combination exclusivity, not a single patent expiration date.
• Real-world safety translates into commercial outcomes: dosing intensity and discontinuation rates directly affect reorder and persistence.

---

FAQs

1) What is AKEEGA’s core therapeutic rationale?

It is a fixed-dose combination that pairs a PARP inhibitor strategy (niraparib) with androgen pathway suppression using abiraterone acetate plus prednisone for mCRPC.

2) What determines whether AKEEGA wins or loses share?

Reimbursement access, sequencing placement by clinicians, and patient persistence driven by tolerability and dose modifications.

3) What KPI best forecasts revenue quality for an oral oncology combination?

Time on therapy (persistence) plus net price realization, not just prescription starts.

4) How does competition typically affect pricing?

Payers often drive net price down once competing regimens secure formulary placement and contracting pressure increases.

5) What is the main long-term risk to value?

Staggered erosion from generic or lower-cost alternatives as component protections and combination exclusivities weaken.

---

References

[1] APA reference entry placeholder.
[2] APA reference entry placeholder.
[3] APA reference entry placeholder.